This trial is active, not recruiting.

Conditions atherosclerosis, aortic aneurysm, peripheral vascular diseases
Sponsor Sheba Medical Center
Collaborator University Hospital Goettingen
Start date March 2001
End date July 2015
Trial size 120 participants
Trial identifier NCT00449306, SHEBA-01-2354-JS-CTIL


Lipid-rich atherosclerotic plaques, or "vulnerable plaques" are prone to rupture, causing local intravascular thrombosis, with subsequent grave clinical consequences. Atherosclerotic plaques normally removed during surgery, and peripheral blood samples will be studied to achieve the following objectives:

"1" Define histological features of the vulnerable plaque, analyze its physical characteristics, and investigate selected gene expression.

"2" Study biomarkers of inflammation in conjunction with the presence of vulnerable plaques.

"3" Explore the potential role of infection in atherogenesis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional

Primary Outcomes

To uncover mechanisms of cardiovascular diseases
time frame: 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Evidence of symptomatic carotid stenosis exceeding 60%(TIAs or stroke within the last 6 months), and asymptomatic carotid artery stenosis (presenting with progressive carotid stenosis, exceeding 70%) - Abdominal aortic aneurysm, and aortic occlusive disease - Peripheral occlusive or aneurysmal disease Exclusion Criteria: - Non-compliant patients, incapable of granting approval by informed consent

Additional Information

Official title Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques
Principal investigator Jacob Schneiderman, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Sheba Medical Center.